Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GH, IMVT, GPCR, PCVX, ALNY, and represent 23.60% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: ALNY (+$248M), MANE (+$184M), GMAB (+$137M), Hemab Therapeutics Holdings (+$132M), BMRN (+$124M), GHRS (+$90M), UTHR (+$67M), AVTX (+$67M), CLDX (+$62M), ALT (+$59M).
- Started 18 new stock positions in UTHR, ALT, IMMX, NKTR, Kardigan Ord, GHRS, ELVN, MNKD, STTK, Hemab Therapeutics Holdings. Kailera Therapeutics, GENB, ALNY, WGS, XNCR, HROW, OLMA, AVTX.
- Reduced shares in these 10 stocks: , Apellis Pharmaceuticals (-$182M), Centessa Pharmaceuticals (-$125M), AXSM (-$98M), IMVT (-$84M), BBIO (-$63M), CYTK (-$57M), TERN (-$57M), MBX (-$57M), IMCR (-$52M).
- Sold out of its positions in ANIP, Apellis Pharmaceuticals, APGE, BLLN, BBIO, Centessa Pharmaceuticals, HELP, Engene Holdings, GERN, JANX. LRMR, XBI, Soleno Therapeutics, TERN, CBIO.
- Deep Track Capital was a net seller of stock by $-547M.
- Deep Track Capital has $6.9B in assets under management (AUM), dropping by 12.20%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Deep Track Capital
Deep Track Capital holds 66 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Guardant Health (GH) | 7.4 | $509M | 3.4M | 150.03 |
|
|
| Immunovant (IMVT) | 5.2 | $360M | -18% | 9.3M | 38.53 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.7 | $254M | +10% | 4.7M | 53.67 |
|
| Vaxcyte (PCVX) | 3.6 | $250M | 4.3M | 58.13 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 3.6 | $248M | NEW | 825k | 301.03 |
|
| Veradermics Common Stock (MANE) | 3.6 | $246M | +300% | 2.0M | 122.94 |
|
| Genmab A/s Sponsored Ads (GMAB) | 3.5 | $238M | +136% | 8.7M | 27.47 |
|
| Tarsus Pharmaceuticals (TARS) | 3.4 | $231M | 3.7M | 62.94 |
|
|
| Nuvalent Inc-a (NUVL) | 3.2 | $220M | +29% | 1.8M | 123.50 |
|
| Alkermes SHS (ALKS) | 3.1 | $210M | +11% | 4.0M | 52.40 |
|
| Ocular Therapeutix (OCUL) | 2.8 | $193M | 20M | 9.82 |
|
|
| BioMarin Pharmaceutical (BMRN) | 2.8 | $189M | +187% | 3.3M | 57.22 |
|
| Nurix Therapeutics (NRIX) | 2.7 | $188M | +21% | 7.7M | 24.26 |
|
| Oruka Therapeutics (ORKA) | 2.7 | $183M | -5% | 1.9M | 95.17 |
|
| Alumis (ALMS) | 2.6 | $179M | -6% | 6.3M | 28.14 |
|
| Ionis Pharmaceuticals (IONS) | 2.5 | $174M | +12% | 2.2M | 79.29 |
|
| Compass Pathways Sponsored Ads (CMPS) | 2.5 | $172M | 12M | 14.15 |
|
|
| Vera Therapeutics Cl A (VERA) | 2.5 | $172M | -2% | 4.0M | 42.91 |
|
| Axsome Therapeutics (AXSM) | 2.5 | $171M | -36% | 700k | 244.77 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.0 | $136M | +9% | 7.0M | 19.47 |
|
| Hemab Therapeutics Hldgs Com Shs | 1.9 | $132M | NEW | 3.6M | 36.73 |
|
| Tango Therapeutics (TNGX) | 1.9 | $131M | +52% | 4.2M | 31.26 |
|
| Definium Therapeutics Com Shs (DFTX) | 1.9 | $129M | -8% | 2.8M | 47.04 |
|
| Grail (GRAL) | 1.8 | $125M | +6% | 1.8M | 68.27 |
|
| Bicara Therapeutics (BCAX) | 1.8 | $122M | 4.1M | 29.69 |
|
|
| Maze Therapeatics (MAZE) | 1.6 | $111M | +7% | 3.7M | 29.84 |
|
| Celldex Therapeutics Com New (CLDX) | 1.6 | $109M | +128% | 2.9M | 37.21 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 1.6 | $109M | 3.4M | 32.45 |
|
|
| Mbx Biosciences (MBX) | 1.4 | $96M | -37% | 1.7M | 55.20 |
|
| Gh Research Ordinary Shares (GHRS) | 1.3 | $90M | NEW | 3.3M | 26.88 |
|
| Cogent Biosciences (COGT) | 1.1 | $77M | +100% | 2.0M | 38.70 |
|
| Ataibeckley Com Shs (ATAI) | 1.1 | $76M | +20% | 14M | 5.27 |
|
| United Therapeutics Corporation (UTHR) | 1.0 | $67M | NEW | 124k | 541.83 |
|
| Avalo Therapeutics Com New (AVTX) | 1.0 | $67M | NEW | 3.6M | 18.48 |
|
| Miragen Therapeutics (VRDN) | 1.0 | $66M | +157% | 3.6M | 18.37 |
|
| Cytokinetics Com New (CYTK) | 0.9 | $60M | -49% | 700k | 85.19 |
|
| Altimmune Com New (ALT) | 0.9 | $59M | NEW | 19M | 3.04 |
|
| Personalis Ord (PSNL) | 0.8 | $54M | +33% | 4.0M | 13.40 |
|
| Aclaris Therapeutics (ACRS) | 0.7 | $49M | 9.3M | 5.29 |
|
|
| Cormedix Inc cormedix (CRMD) | 0.7 | $49M | 6.3M | 7.85 |
|
|
| Genedx Holdings Corp Com Cl A (WGS) | 0.7 | $48M | NEW | 700k | 68.65 |
|
| Harrow Health (HROW) | 0.6 | $41M | NEW | 969k | 42.47 |
|
| Corvus Pharmaceuticals (CRVS) | 0.5 | $37M | 2.5M | 14.94 |
|
|
| Solid Biosciences Com New (SLDB) | 0.5 | $36M | 3.6M | 9.99 |
|
|
| Beam Therapeutics (BEAM) | 0.5 | $34M | +21% | 1.0M | 34.32 |
|
| Dyne Therapeutics (DYN) | 0.5 | $33M | -25% | 1.5M | 22.21 |
|
| Immix Biopharma (IMMX) | 0.4 | $29M | NEW | 2.8M | 10.31 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.4 | $28M | -7% | 5.9M | 4.67 |
|
| Shattuck Labs (STTK) | 0.4 | $26M | NEW | 3.7M | 6.94 |
|
| Mannkind Corp Com New (MNKD) | 0.4 | $26M | NEW | 6.0M | 4.26 |
|
| Century Therapeutics (IPSC) | 0.3 | $23M | 9.5M | 2.45 |
|
|
| Generate Biomedicines Com Shs (GENB) | 0.3 | $23M | NEW | 1.3M | 16.87 |
|
| Verastem Com New (VSTM) | 0.3 | $22M | 5.7M | 3.82 |
|
|
| Kura Oncology (KURA) | 0.3 | $22M | -25% | 2.0M | 10.97 |
|
| Enanta Pharmaceuticals (ENTA) | 0.3 | $21M | -26% | 1.4M | 14.58 |
|
| Nektar Therapeutics Com New (NKTR) | 0.3 | $21M | NEW | 300k | 69.81 |
|
| Olema Pharmaceuticals (OLMA) | 0.3 | $19M | NEW | 1.5M | 12.51 |
|
| Kailera Therapeutics Common Stock | 0.2 | $15M | NEW | 700k | 22.03 |
|
| Kardigan Ord | 0.2 | $14M | NEW | 600k | 23.85 |
|
| Enliven Therapeutics (ELVN) | 0.2 | $11M | NEW | 225k | 50.75 |
|
| Promis Neurosciences Com Shs (PMN) | 0.2 | $11M | 836k | 13.16 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.1 | $9.9M | -83% | 311k | 31.75 |
|
| Xencor (XNCR) | 0.1 | $9.6M | NEW | 594k | 16.10 |
|
| Context Therapeutics (CNTX) | 0.1 | $4.1M | 7.4M | 0.55 |
|
|
| Inventiva Sa Ads (IVA) | 0.0 | $3.0M | -34% | 800k | 3.78 |
|
| Aligos Therapeutics Com New (ALGS) | 0.0 | $2.6M | 444k | 5.77 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2026 Q2 filed Aug. 14, 2026
- Deep Track Capital 2026 Q1 filed May 15, 2026
- Deep Track Capital 2025 Q4 filed Feb. 13, 2026
- Deep Track Capital 2025 Q3 filed Nov. 14, 2025
- Deep Track Capital 2025 Q2 filed Aug. 14, 2025
- Deep Track Capital 2025 Q1 filed May 15, 2025
- Deep Track Capital 2024 Q4 filed Feb. 14, 2025
- Deep Track Capital 2024 Q3 filed Nov. 14, 2024
- Deep Track Capital 2024 Q2 filed Aug. 14, 2024
- Deep Track Capital 2024 Q1 filed May 15, 2024
- Deep Track Capital 2023 Q4 filed Feb. 14, 2024
- Deep Track Capital 2023 Q3 filed Nov. 14, 2023
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023